Table 1. Patient Characteristics for the Total Cohort and According to Cardiac Events Between March 23 and April 21, 2020.
| Characteristic | Patients, No. (%) | P value | ||
|---|---|---|---|---|
| Total study cohort (N = 77) | TAVR or death (n = 8) | No TAVR or death (n = 69) | ||
| Age, mean (SD), y | 80 (8) | 82 (8) | 79 (8) | .90 |
| Male | 49 (64.0) | 4 (50.0) | 45 (65.2) | .40 |
| Body mass index, mean (SD)a | 27.2 (5) | 27.4 (5) | 27.2 (4) | .90 |
| Hypertension | 73 (94.0) | 8 (100.0) | 65 (94.2) | .40 |
| Diabetes | 34 (44.2) | 3 (37.5) | 31 (44.9) | .70 |
| Chronic kidney disease | 37 (48.1) | 3 (37.5) | 34 (49.2) | .50 |
| End-stage kidney disease | 8 (10.1) | 1 (12.5) | 7 (10.1) | .80 |
| Left ventricular ejection fraction, mean (SD), % | 55 (14) | 45 (16) | 56 (14) | .04 |
| Cerebrovascular accident | 9 (11.4) | 2 (25.0) | 7 (10.1) | .20 |
| Transient ischemic attack | 2 (2.5) | 0 | 2 (2.9) | .60 |
| Prior permanent pacemaker | 7 (8.9) | 1 (12.5) | 6 (8.7) | .70 |
| Coronary artery bypass grafting | 11 (14.3) | 2 (25.0) | 9 (13.0) | .40 |
| Coronary artery disease | 42 (54.5) | 7 (87.5) | 35 (50.7) | .048 |
| Atrial fibrillation | 24 (31.2) | 2 (25.0) | 22 (31.9) | .70 |
| Congestive heart failure | 29 (37.7) | 5 (62.5) | 24 (34.8) | .10 |
| Aortic valve gradient, mean (SD), mm Hg | 34 (13) | 36 (9) | 34 (14) | .80 |
| Aortic valve area, mean (SD), cm2 | 0.8 (0.2) | 0.7 (0.2) | 0.8 (0.2) | .30 |
| New York Heart Association symptom class | ||||
| I | 8 (10.4) | 0 | 8 (11.6) | .02 |
| II | 31 (40.3) | 0 | 31 (44.9) | |
| III | 33 (42.9) | 7 (87.5) | 26 (37.7) | |
| IV | 2 (2.6) | 1 (12.5) | 1 (1.4) | |
Abbreviation: TAVR, transcatheter aortic valve replacement.
a
Body mass index is calculated as weight in kilograms divided by height in meters squared.